Amanta healthcare Limited has filed its mandatory quarterly compliance certificate with the Bombay Stock Exchange and National Stock Exchange of India for the quarter ended March 31, 2026. The submission, dated April 8, 2026, fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Nikhita Dinodia signed the submission on behalf of Amanta Healthcare Limited, ensuring adherence to prescribed timelines for regulatory filings.

Registrar Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, served as the company's Registrar and Share Transfer Agent for the quarter. The registrar, holding SEBI Registration No. INR000004058, issued the confirmation certificate dated April 1, 2026.

Sr. Vice President-Corporate Registry Ashok Shetty signed the registrar's certificate, confirming compliance with dematerialization procedures. The certificate validates that all securities received from depository participants during the quarter were properly processed within prescribed timelines.

Dematerialization Process Compliance

The registrar confirmed several key compliance aspects for the quarter:

• Securities received for dematerialization were confirmed to depositories
• All security certificates were properly accepted or rejected
• Listed securities maintained consistency with existing stock exchange listings
• Security certificates were mutilated and cancelled after verification
• Depository names were substituted in the register of members

Corporate Information

Amanta Healthcare Limited operates from its registered and corporate office located at 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad-380058, Gujarat. The company maintains its corporate identification number as L24139GJ1994PLC023944, reflecting its incorporation status in Gujarat.

The filing demonstrates the company's commitment to maintaining regulatory compliance and transparent communication with stock exchanges and regulatory authorities.

Amanta healthcare Limited has filed its annual regulatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ended March 31, 2026. The company submitted the mandatory compliance documents to both stock exchanges on April 2, 2026.

Regulatory Filing Details

The disclosures were filed under Regulation 31(4) of SEBI SAST Regulations with both BSE Limited and National Stock Exchange of India Limited. The company maintains its listing on both exchanges with specific identifiers for trading purposes.

Promoter Group Declaration

Chairman & Managing Director Bhavesh G. Patel, representing the promoter and promoter group, has made a comprehensive declaration regarding share encumbrance. The promoter group has confirmed that no encumbrance was created, directly or indirectly, on the shares or securities of Amanta Healthcare Limited during the financial year 2025-26.

This declaration ensures transparency in promoter holdings and compliance with SEBI's substantial acquisition and takeover regulations. The filing demonstrates the company's commitment to maintaining proper corporate governance standards and regulatory adherence.

Corporate Compliance

The annual disclosures were executed by key company officials to ensure proper authorization and compliance. Company Secretary & Compliance Officer Nikhita Dinodia coordinated the filing process, while promoter Bhavesh Girishbhai Patel provided the necessary declarations on behalf of the promoter group.

The company operates from its registered and corporate office located at 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad-380058, Gujarat. These annual disclosures form part of the company's ongoing regulatory obligations as a listed entity, ensuring transparency in promoter activities and shareholding patterns for investor protection and market integrity.